The U.S. Food and Drug Administration wants an updated label for Amgen Inc.'s Enebrel to include warnings that the rheumatoid arthritis drug can be deadly when taken by children, and that the drug can cause serious infections in adults, the Wall Street Journal reported Monday.
In documents posted on its Web site, the FDA said infections, malignancies and neurological problems have been reported among children who have used the drug. These problems are similar to those experienced by some adults, the newspaper reported.
